MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call a ...

Core Viewpoint - ZimVie Inc. has entered into a definitive agreement to be acquired by ARCHIMED, an investment firm focused on healthcare industries, for $19.00 per share, representing a 99% premium over its recent trading price, with an enterprise value of approximately $730 million [2][3]. Company Overview - ZimVie is a global leader in the dental implant market, developing and delivering a comprehensive portfolio of products aimed at supporting dental tooth replacement and restoration procedures [8]. - The company is headquartered in Palm Beach Gardens, Florida, and is committed to advancing clinical science and technology in the dental sector [8]. Acquisition Details - Under the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share, with the transaction expected to close by year-end 2025, pending customary closing conditions [2][4]. - The Board of Directors of ZimVie has unanimously approved the transaction, which is not subject to a financing condition [4]. - Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ [5]. Strategic Implications - The acquisition is expected to provide ZimVie with the strategic and financial backing necessary to expand its innovative dental technology globally [3]. - ARCHIMED views ZimVie as having strong fundamentals and compelling growth potential, indicating a positive outlook for the company's future [3]. Go-Shop Period - ZimVie has a 40-day go-shop period during which it can solicit proposals from third parties, ending on August 29, 2025 [6]. - There is no assurance that this solicitation process will yield a superior proposal [6]. Advisory Roles - Centerview Partners is serving as the exclusive financial advisor to ZimVie, while UBS Investment Bank is the exclusive financial advisor to ARCHIMED [7].

Core Viewpoint - Abbott Laboratories reported better-than-expected sales and profits for the second quarter but reduced earnings and growth projections for the remainder of the year [1][2]. Financial Performance - Second-quarter sales reached $11.14 billion, surpassing the consensus estimate of $11.07 billion [1]. - Adjusted earnings for the second quarter were $1.26 per share, exceeding the consensus of $1.25 and falling within the management's guidance of $1.23-$1.27 [1]. Growth Projections - For full-year 2025, Abbott narrowed its adjusted earnings guidance from a range of $5.05-$5.25 per share to $5.10-$5.20 per share, compared to the consensus of $5.16 [2]. - The company expects organic sales growth of 7.5%-8.0%, slightly down from the previous guidance of 7.5%-8.5% [2]. Margin Expectations - Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, unchanged from prior guidance but lower than the previous range of 23.5%-24.0% [3]. - The expected adjusted earnings for the third quarter of 2025 are projected to be between $1.28 and $1.32 per share, below the consensus of $1.34 per share [3]. Market Reaction - Following the earnings announcement, Abbott's shares fell by 8.5%, closing at $120.51 [3]. Analyst Ratings - BTIG analyst maintained a Buy rating but lowered the price target from $148 to $145 [5]. - Jefferies analyst upgraded Abbott from Hold to Buy and raised the price target from $143 to $145 [5]. - Mizuho analyst maintained a Neutral rating and reduced the price target from $140 to $135 [5].

Core Insights - Anumana's FDA-cleared LEF algorithm is the first certified third-party solution available through Philips' ECG ecosystem, enhancing cardiac care capabilities [1][3] - The Philips ECG AI Marketplace provides a centralized platform for U.S. hospitals to integrate various AI-powered diagnostic tools, improving workflow and efficiency [2][4] Company Developments - Philips has launched the ECG AI Marketplace, allowing cardiac care teams to access multiple AI tools, which streamlines the diagnostic process and reduces the time for ECG result reviews [2][3] - Anumana's LEF algorithm, which identifies reduced ejection fraction as an early indicator of heart failure, is now integrated into Philips' ECG portfolio, including IntelliSpace ECG and Philips cardiographs [3][4] Industry Impact - The collaboration between Philips and Anumana aims to improve early detection of cardiovascular diseases and enhance patient care through AI diagnostics [3][4] - Anumana's algorithms have been validated in studies involving over 150,000 patients and are supported by nearly 100 peer-reviewed publications, indicating a strong foundation for clinical application [4]

Core Insights - Johnson & Johnson reported Q2 2025 earnings with sales of $23.7 billion, a 4.6% increase, and adjusted EPS of $2.77, with net earnings of $5.5 billion, leading to an increase in full-year sales and EPS guidance [1] - The company is focusing on strategic execution, diversified growth drivers, and pipeline achievements to enhance its long-term investment profile [2] Business Performance - Despite a 43.2% year-over-year revenue decline for Stelara due to biosimilar competition, innovative medicine sales rose 3.8% operationally, and medtech achieved 6.1% operational sales growth, driven by a 22% increase in cardiovascular segment sales [3] - Excluding Stelara, 90% of the business experienced robust growth of 15.5%, with 13 brands achieving double-digit growth, showcasing the company's resilience [4] Oncology Growth Strategy - The oncology franchise saw a 22.3% growth, with a significant portion of multiple myeloma patients using Johnson & Johnson products, and management aims to become the global leader in oncology by 2030 with projected sales exceeding $50 billion annually [5] - The TAR-200 product is expected to significantly outperform market expectations, positioning Johnson & Johnson as a top-tier oncology growth platform [6] MedTech Developments - Medtech's cardiovascular segment achieved 22% sales growth, supported by acquisitions and maintaining its status as the fastest-growing company in the cardiovascular medtech space [7] - The electrophysiology business reported $5 billion in sales with 9.8% growth, benefiting from strong physician adoption and product innovations [8] Future Outlook - Management guided for full-year 2025 sales growth of 5.1%-5.6%, raising the midpoint of sales guidance to $93.4 billion and adjusted EPS guidance to $10.80-$10.90, with key pipeline catalysts expected in the second half of 2025 [9]

BROSSARD, Quebec, July 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian leader in artificial intelligence (AI) for the early detection of retinal and systemic diseases, is proud to announce that it has formally submitted a Pre-Submission (Q-sub) to the U.S. Food and Drug Administration (FDA) for its flagship CARA System. This filing marks the first strategic step toward regulatory clearance and commercial deployment in the U.S ...

Carlsmed, a medical technology company that uses AI to personalize spine surgery, is seeking to raise as much as $107.2 million in a US IPO https://t.co/Z5je1FkV3q ...

Company Leadership Transition - Steven Pfanstiel has been appointed as the new Chief Financial Officer of Neuronetics, effective July 15, 2025, replacing Steve Furlong, who will retire on March 31, 2026 [2][3] - Steve Furlong will continue to serve as Senior Advisor to the CEO during the transition period to ensure operational continuity [2][3] Executive Background - Steven Pfanstiel brings over two decades of healthcare experience, having previously served as CFO and COO at Marinus Pharmaceuticals, where he was instrumental in the launch of the flagship product, Ztalmy [3][4] - Pfanstiel has held senior financial roles at various high-growth healthcare companies, including Lifescan and Optinose, and has experience at Johnson & Johnson across multiple product categories [3][4] Strategic Vision and Growth - Neuronetics aims to expand access to mental health treatments and deliver sustainable growth, leveraging Pfanstiel's expertise in financial leadership and growth strategies [3][4] - The company is focused on integrating Greenbrook operations and achieving positive cash flow in the third quarter of 2025, marking a significant operational milestone [5] Stock Incentives - As part of his employment agreement, Pfanstiel received an inducement grant of 400,000 restricted stock units, with specific vesting schedules tied to his continued employment [4] Company Performance and Market Position - Neuronetics reaffirms its guidance for the second quarter and full year 2025, driven by successful integration efforts and key growth drivers [5] - The company operates Greenbrook TMS treatment centers across the U.S., offering NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD) [6][7]

Core Insights - The World Artificial Intelligence Conference (WAIC) 2025 will focus on AI's role in transforming the healthcare industry, addressing challenges from data governance to clinical application [3][25] - The event will feature multiple forums discussing key areas such as diagnostic innovation, AI drug development, clinical applications, and healthcare accessibility [3][5] Group 1: Event Details - WAIC 2025 will take place from July 26 to July 28, 2025, at the Shanghai World Expo Center and the Shanghai World Expo Exhibition Hall [3] - The exhibition area will exceed 70,000 square meters, showcasing over 30 healthcare technologies and products [17] Group 2: Key Forums and Discussions - The healthcare segment will include four major forums focusing on AI's impact on medical diagnostics, drug development, clinical applications, and equitable healthcare [3][5] - A forum titled "AI Empowering New Paradigms in Medicine and Health" will feature discussions led by Nobel laureates and Turing Award winners on transformative research and drug development [5][14] Group 3: Innovations and Technologies - The conference will unveil several technological advancements, including AI-driven drug development optimization solutions and global medical imaging AI analysis platforms [15] - Notable companies like Alibaba and Ant Group will present innovative AI medical imaging diagnostic systems [18] Group 4: Global Participation - The event will gather international research institutions, hospitals, and universities, including the Royal Academy of Engineering and Stanford University School of Medicine [9][11] - Experts from various fields will engage in high-level dialogues on the application of AI in healthcare, addressing macro industry development and clinical applications [6][25]

Group 1 - Integra LifeSciences Holdings Corporation will release its second quarter 2025 financial results on July 31, 2025, before the market opens [1] - A conference call hosted by Integra's management team will take place at 8:30 a.m. ET on the same day [1] - A live webcast of the conference call will be available on the Investors section of the company's website [2] Group 2 - Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways and advancing patient outcomes [3] - The company offers a comprehensive portfolio of high-quality, leadership brands in surgical, neurologic, and regenerative care [3] - For more information about Integra and its products, the company encourages visiting its website [3]